Effects of GF-015535-00, a novel α1 GABAA receptor ligand, on the sleep-wake cycle in mice, with reference to zolpidem

Sleep

Volumn 35, Issue 1, 2012, Pages 103-111

  Anaclet, Christelle ^a   Zhang, Mei ^a,b   Zhao, Chunmei ^a,c   Buda, Colette ^a   Seugnet, Laurent ^a   Lin, Jian Sheng ^a  

^a UNIVERSITÉ LYON 1   (France)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

1 GABAA receptor; Insomnia; Mouse; Sleep fragmentation; Zolpidem

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR ALPHA1; GF 01553500; UNCLASSIFIED DRUG; ZOLPIDEM;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ELECTROENCEPHALOGRAM; MALE; MOUSE; NONHUMAN; POWER ANALYSIS; PRIORITY JOURNAL; REM SLEEP; SLEEP INDUCTION; SLEEP WAKING CYCLE; SLOW WAVE SLEEP;

ANIMALS; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROENCEPHALOGRAPHY; HYPNOTICS AND SEDATIVES; MALE; MICE; MICE, INBRED C57BL; PYRIDINES; RECEPTORS, GABA-A; SLEEP; SLEEP STAGES;

EID: 84863015290     PISSN: 01618105     EISSN: 15509109     Source Type: Journal    
DOI: 10.5665/sleep.1596     Document Type: Article

References (25)

1. Wafford KA, Ebert B. Emerging anti-insomnia drugs: tackling sleeplessness and the quality of wake time. Nat Rev Drug Discov 2008;7:530-40. (Pubitemid 351767120)
2. Roth T, Drake C. Evolution of insomnia: current status and future direction. Sleep Med 2004;5:S23-30. (Pubitemid 39149160)
3. Sateia MJ, Nowell PD. Insomnia. Lancet 2004;364:1959-73. (Pubitemid 39574600)
4. McKernan RM, Whiting PJ. Which GABAA-receptor subtypes really occur in the brain? Trends Neurosci 1996;19:139-43.
5. Barnard EA, Skolnick P, Olsen RW, et al. International Union of Pharmacology. XV. Subtypes of gamma-aminobutyric acid-A receptors: classification on the basis of subunit structure and receptor function. Pharmacol Rev 1998;50:291-313. (Pubitemid 28304030)
6. Mohler H, Fritschy JM, Rudolph U. A new benzodiazepine pharmacology. J Pharmacol Exp Ther 2002;300:2-8. (Pubitemid 34028501)
7. Rudolph U, Crestani F, Benke D, et al. Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature 1999;401:796-800.
8. Mitler MM. Nonselective and selective benzodiazepine receptor agonists- -where are we today? Sleep 2000;23:S39-47.
9. Drover DR. Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone. Clin Pharmacokinet 2004;43:227-38. (Pubitemid 38429303)
10. Terzano MG, Rossi M, Palomba V, Smerieri A, Parrino L. New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. Drug Saf 2003;26:261-82. (Pubitemid 36363607)
11. Stienen PJ, Pérez C, Alcántara AM, et al. In vivo pharmacological profile of GF-015535-00, a novel non-benzodiazepine sedative-hypnotic. Society for Neuroscience Annual Meeting. Chicago IL, USA; 2009.
12. Stienen PJ, Pérez C, Alcántara AM, et al. CNS pharmacology of a novel nonbenzodiazepine hypnotic, GF-015535-00, for the treatment of insomnia. Society for Neuroscience Annual Meeting. San Diego CA, USA; 2010.
13. Alexandre C, Dordal A, Aixendri R, Guzman A, Hamon M, Adrien J. Sleep-stabilizing effects of E-6199, compared to zopiclone, zolpidem and THIP in mice. Sleep 2008;31:259-70. (Pubitemid 351536528)
14. Lancel M. Role of GABAA receptors in the regulation of sleep: initial sleep responses to peripherally administered modulators and agonists. Sleep 1999;22:33-42. (Pubitemid 29097897)
15. Wagner J, Wagner ML. Non-benzodiazepines for the treatment of insomnia. Sleep Med Rev 2000;4:551-581.
16. Valatx JL. [Long-term recording of cerebral, muscular and ocular electric activities in mice]. C R Seances Soc Biol Fil 1971;165:112-5 .
17. Valatx JL, Bugat R. [Genetic factors as determinants of the waking-sleep cycle in the mouse (author's transl)]. Brain Res. 1974;69:315-30.
18. Parmentier R, Ohtsu H, Djebbara-Hannas Z, Valatx JL, Watanabe T, Lin JS. Anatomical, physiological, and pharmacological characteristics of histidine decarboxylase knock-out mice: evidence for the role of brain histamine in behavioral and sleep-wake control. J Neurosci 2002;22:7695-711. (Pubitemid 35386369)
19. Anaclet C, Parmentier R, Ouk K, et al. Orexin/hypocretin and histamine: distinct roles in the control of wakefulness demonstrated using knock-out mouse models. J Neurosci 2009;29:14423-38.
20. Zammit G. Comparative tolerability of newer agents for insomnia. Drug Saf 2009;32:735-48.
21. Gottesmann C, Gandolfo G, Arnaud C, Gauthier P. The intermediate stage and paradoxical sleep in the rat: influence of three generations of hypnotics. Eur J Neurosci. 1998;10:409-14. (Pubitemid 28325464)
22. Landolt HP, Finelli LA, Roth C, Buck A, Achermann P, Borbely AA. Zolpidem and sleep deprivation: different effect on EEG power spectra. J Sleep Res 2000;9:175-83. (Pubitemid 30333151)
23. Wallace MB. Hypnotic medications: mechanisms of action and pharmacologic effects. In: Kryger MH, Roth T, Dement WC, eds. Principles and practice of sleep medicine. 4th ed. Elsevier Saunders; 2005:444-51.
24. Edinger JD, Means MK. Overview of insomnia: definitions, epidemiology, differential diagnosis and assessment. In: Kryger MH, Roth T, Dement WC, eds. Principles and practice of sleep medicine. 4th ed. Elsevier Saunders; 2005:702-13.
25. Kopp C, Rudolph U, Tobler I. Sleep EEG changes after zolpidem in mice. Neuroreport 2004;15:2299-302. (Pubitemid 39392259)